CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 167 enrolled
Drug / intervention
Accessible Care +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03214679
NCT03214679N/ACompleted

Accessible Care Intervention for Engaging People Who Inject Illicit Drugs in HCV Care

City University of New York, School of Public Health·interventional·Posted Jul 11, 2017·Updated Feb 22, 2023

In Brief

A clinical study evaluating Accessible Care and Usual Care for Hepatitis C and 3 related conditions. Completed, enrolled 167 participants across 1 site.

Detailed Summary

The proposed study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID) in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs designed specifically for PWID where they can comfortably access care without fear of shame or stigma. Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator (HCCC), on-site at a collaborating needle exchange program. The proposed study will compare the effectiveness of Accessible Care with Usual Care (referrals to existing services) in facilitating linkage, engagement, and retention of PWID in care for hepatitis C, addiction, and HIV prevention. The primary outcome is sustained virologic response, which constitutes virologic cure. Substance use and HIV and HCV risk behaviors are secondary outcomes.

Study Details

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 11, 2017
Enrollment StartJul 20, 2017
Primary CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.0 years ago

Interventions

Accessible Careother

Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.

Usual Careother

Usual care entails referral to an on site HCV care coordinator (not provided by study)